Multinational Retrospective Central Pathology Review of Neuroblastoma
Abstract
Context.—Several countries of the Central America and Caribbean region have been sharing regional neuroblastoma (NB) treatment guidelines. However, there is no standardization in the diagnosis, subclassification, or tumor biology to aid in the risk stratification of these patients. Objective.—To examine the histology and assess the accuracy of the local pathology reports; to evaluate the usefulness of manual MYCN immunohistochemistry (IHC); and to use NB as a model to identify the needs to establish a central pathology review (CPR) program in this region. Design.—A retrospective CPR of specimens derived from patients with a diagnosis of NB and treated under the regional NB guidelines between 2012 and 2017 was conducted, allowing for a comparison between local diagnoses and the CPR diagnoses. Manual MYCN IHC was performed in the confirmed NB specimens and the results compared with known fluorescence in situ hybridization or automated IHC results, when available. Results.—The 156 specimens reviewed included 460 blocks and 183 original slides. Neuroblastoma was confirmed in 138 samples (88.5%), but low concordance rates for Shimada classification (n = 39; 25.0%), mitotickaryorrhectic index (n = 4; 2.5%), and International Neuroblastoma Pathology Classification (n = 18; 11.5%) were noted. Manual MYCN IHC performed on 120 specimens showed conclusive results in 89.2% (28 positive, 23.4%; 79 negative, 65.8%) and questionable results in 10.8% (n = 13). Conclusions.—This retrospective CPR highlights the need for a CPR program to serve this region, to ensure correct diagnosis and subclassification of NB, and to provide manual MYCN IHC—with reflexing to fluorescence in situ hybridization, if questionable. This approach can further regional collaboration, enhance test utilization, and ultimately improve patients’ outcomes. (Arch Pathol Lab Med. 2021;145:214–221. Doi: 10.5858/arpa. 2019-0570-OA).
Downloads
References
Luna-Fineman S, Barnoya M, Bonilla M, Fu L, Baez F, Rodriguez- Galindo C. Retinoblastoma in Central America: report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr Blood Cancer. 2012; 58(4):545–550.
Castellanos EM, Barrantes JC, Baez LF, et al. A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999. Pediatr Blood Cancer. 2014; 61(6):997– 1002.
Navarrete M, Rossi E, Brivio E, et al. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience. Pediatr Blood Cancer. 2014; 61(5):803–809.
Ceppi F, Ortiz R, Antillon F, et al. Anaplastic large cell lymphoma in Central America: a report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr Blood Cancer. 2016; 63(1):78–82.
Santiago TC, Jenkins JJ. Histopathologic diagnosis of pediatric neoplasms: a review of international consultations. Arch Pathol Lab Med. 2013; 137(11):1648–1653.
Santiago T, Hayes C, Polanco AC, et al. Improving immunohistochemistry capability for pediatric cancer care in the Central American and Caribbean region: a report from the AHOPCA Pathology Working Group. J Glob Oncol. 2018; 4:1–9.
Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364–372.
Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clinl Oncol. 2009; 27(2):289–297.
Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization: diagnostic utility for neuroblastoma. Am J Pathol. 1993; 142(5):1339–1346.
Quintana Y, Patel AN, Arreola M, Antillon FG, Ribeiro RC, Howard SC. POND4Kids: a global web-based database for pediatric hematology and oncology outcome evaluation and collaboration. Stud Health Technol Inform. 2013; 183:251–256.
Santiago T, Tarek N, Boulos F, et al. Correlation between MYCN gene status and MYCN protein expression in neuroblastoma: a pilot study to propose the use of MYCN immunohistochemistry in limited-resource areas. J Glob Oncol. 2019(5):1–7.
Vujanic GM, Sandstedt B, Kelsey A, Sebire NJ. Central pathology review in multi-center trials and studies: lessons from the nephroblastoma trials. Cancer. 2009; 115(9):1977–1983.
Jackson TJ, Williams RD, Brok J, et al. The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: report of the UK experience in the SIOP UK WT 2001 trial. Pediatr Blood Cancer. 2019; 66(6):e27627.
Vujani´c GM, Gessler M, Ooms AHAG, et al. The UMBRELLA SIOP–RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018; 15(11):693–701.
Teot LA, Sposto R, Khayat A, Qualman S, Reaman G, Parham D. The problems and promise of central pathology review: development of a standardized procedure for the Children’s Oncology Group. Pediatr Dev Pathol. 2007; 10(3):199–207.
Mroz P, Parwani AV, Kulesza P. Central pathology review for phase III clinical trials: the enabling effect of virtual microscopy. Arch Pathol Lab Med. 2013; 137(4):492–495.
Hedvat CV. Digital microscopy: past, present, and future. Arch Pathol Lab Med. 2010; 134(11):1666–1670. Arch Pathol Lab Med. 2010; 134(11):1666–1670.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Los textos académicos y científicos que se publican en la Revista La Universidad están protegidos bajo la licencia CC BY NC SA 4.0, esta permite usar una obra para crear otra obra o contenido, modificando o no la obra original, siempre que se cite al autor, la obra resultante se comparta bajo el mismo tipo de licencia y no tenga fines comerciales (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es) . El autor es el único que pose los derechos de publicación y la Revista La Universidad posee los derechos de difusión.
